WST · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

WEST PHARMACEUTICAL SERVICES INC · 2026-10-29 · Importance 60 · Surprise 40 · In source text

For the three months ended September 30, 2026, consolidated organic net sales grew 11.9% year over year, with volume and mix contributing $58.3 million and price increases contributing $33.6 million. Proprietary Products organic net sales increased 16.6%; HVP component sales grew 20.3% on continued strong demand for biologics and GLP-1 products, while HVP delivery-device sales rose 26.4%, driven primarily by demand for Daikyo Crystal Zenith® and Administration Systems. For the nine months, HVP component sales increased 20.4%, supported by biologics and GLP-1 demand, and HVP delivery-device sales rose 27.9%, reflecting higher first-half demand for self-injection devices and higher Daikyo Crystal Zenith® sales. West Vantage organic sales declined 6.6% in the quarter and 0.2% for the nine months, primarily because a continuous glucose monitoring customer contract expired at one facility, partly offset by sales of self-injection devices for diabetes and obesity and device components.

Key facts

• WEST PHARMACEUTICAL SERVICES INC’s HVP components sales increased $216.0 million, or 20.4%, in the nine months ended September 30, 2026, excluding foreign currency translation effects, driven by Biologics and GLP-1 demand and sales price increases. source
• WEST PHARMACEUTICAL SERVICES INC’s consolidated net sales organically increased $91.9 million, or 11.9%, in the three months ended September 30, 2026; volume and mix contributed $58.3 million and sales price increases contributed $33.6 million. source
• WEST PHARMACEUTICAL SERVICES INC’s Proprietary Products net sales organically increased $102.3 million, or 16.6%, in the three months ended September 30, 2026; HVP components contributed approximately 13 percentage points of organic sales growth and HVP delivery devices a further 3 percentage points. source
• WEST PHARMACEUTICAL SERVICES INC’s consolidated net sales organically increased $296.1 million, or 13.2%, in the nine months ended September 30, 2026; volume and mix contributed $208.0 million and sales price increases contributed $88.1 million. source
• WEST PHARMACEUTICAL SERVICES INC’s HVP components sales increased $79.1 million, or 20.3%, in the three months ended September 30, 2026, excluding foreign currency translation effects, driven by Biologics and GLP-1 customer demand and sales price increases. source
• WEST PHARMACEUTICAL SERVICES INC’s HVP delivery devices sales increased $74.3 million, or 27.9%, in the nine months ended September 30, 2026, excluding foreign currency translation effects and the SmartDose® 3.5mL revenue reduction. source
• WEST PHARMACEUTICAL SERVICES INC’s HVP delivery devices sales increased $18.3 million, or 26.4%, in the three months ended September 30, 2026, excluding foreign currency translation effects and SmartDose® 3.5mL; growth was driven primarily by demand for Daikyo Crystal Zenith® and Administration Systems. source
• WEST PHARMACEUTICAL SERVICES INC’s West Vantage net sales decreased $10.4 million, or 6.6%, organically in the three months ended September 30, 2026, primarily because of the planned expiration of a continuous glucose monitoring customer contract at one facility, partially offset by price increases and sales increases in diabetes and obesity self-injection devices and device components. source

Impact estimates